Overall, our preliminary results identify the CD137 death receptor as a putative novel regulator BM-mediated protection in the context of MPN disease and we are currently intensifying our studies to further exploit the therapeutic applications of this receptor as well as the molecular mechanisms behind it. Here, TNFRSF9 is linked to myeloproliferative neoplasm.